| Identification | Back Directory | [Name]
Viquidacin | [CAS]
904302-98-3 | [Synonyms]
NXL 101
Viquidacin
USGHRRVFKSLEJT-WVBUVRCRSA-N
3-Piperidinecarboxylic acid, 4-[(3S)-3-(3-fluoro-6-methoxy-4-quinolinyl)-3-hydroxypropyl]-1-[2-(2-thienylthio)ethyl]-, (3R,4R)- | [Molecular Formula]
C25H29FN2O4S2 | [MDL Number]
MFCD13152405 | [MOL File]
904302-98-3.mol | [Molecular Weight]
504.64 |
| Hazard Information | Back Directory | [Uses]
Viquidacin (NXL 101) is an antibiotic with inhibitory activity against topoisomerase IV and DNA gyrase. Viquidacin exhibits antibacterial activity against gram positive bacterial by inhibiting the supercoiling, decatenation and relaxation in strains Staphylococcus aureus and Escherichia coli in micromolar levels. Viquidacin inhibits S. aureus wildtype and mutants with MIC of 2-128 mg/L[1]. | [References]
[1] Black MT, et al., Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother. 2008 Sep;52(9):3339-49. DOI:10.1128/AAC.00496-08 |
|
|